• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Noble Capital Markets initiated coverage on Gyre Therapeutics

    3/11/25 10:02:24 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GYRE alert in real time by email
    Noble Capital Markets initiated coverage of Gyre Therapeutics with a rating of Outperform
    Get the next $GYRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GYRE

    DatePrice TargetRatingAnalyst
    3/11/2025Outperform
    Noble Capital Markets
    More analyst ratings

    $GYRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Grou

      1/6/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

      SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company's Board of Directors and as a member of its Audit Committee. "Rodney has an extensive background in finance, accounting, and financial reporting with nearly four decades of experience working at global auditing and consulting firms," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies. We look forwa

      3/21/24 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Financials

    Live finance-specific insights

    See more
    • Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

      5/9/25 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full

      3/17/25 4:15:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

      Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f

      11/13/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ye Weiguo exercised 650,000 shares at a strike of $0.75 (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      4/25/25 4:01:13 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Eastling Thomas Wilson exercised 15,000 shares at a strike of $6.93 (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      4/18/25 5:27:15 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $1,740 worth of shares (174 units at $10.00) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/25/25 4:01:33 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Gyre Therapeutics Inc.

      10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/9/25 4:30:37 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/8/25 8:30:09 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      4/28/25 7:05:24 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

      5/9/25 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

      SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People's Republic of China ("PRC") has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications. The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP). This regulatory milestone marks the expansion of pirfenidone beyond its established role in idiopathic pulmonary fibrosis (

      3/31/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

      SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled "Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial" in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B ("CHB"). The published protocol outlines patient inclusion criteria,

      3/27/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:31:07 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:15:45 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Gyre Therapeutics

      Noble Capital Markets initiated coverage of Gyre Therapeutics with a rating of Outperform

      3/11/25 10:02:24 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care